FI965032L - Interleukiini-5-spesifisiä yhdistelmä-vasta-aineita - Google Patents

Interleukiini-5-spesifisiä yhdistelmä-vasta-aineita Download PDF

Info

Publication number
FI965032L
FI965032L FI965032A FI965032A FI965032L FI 965032 L FI965032 L FI 965032L FI 965032 A FI965032 A FI 965032A FI 965032 A FI965032 A FI 965032A FI 965032 L FI965032 L FI 965032L
Authority
FI
Finland
Prior art keywords
interleukin
recombinant antibodies
specific recombinant
specific
antibodies
Prior art date
Application number
FI965032A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI965032A0 (fi
FI965032A7 (fi
Inventor
John Spencer Emtage
Mark William Bodmer
Diljeet Singh Anthwal
Original Assignee
Celltech Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Therapeutics Ltd filed Critical Celltech Therapeutics Ltd
Publication of FI965032A0 publication Critical patent/FI965032A0/fi
Publication of FI965032L publication Critical patent/FI965032L/fi
Publication of FI965032A7 publication Critical patent/FI965032A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI965032A 1994-06-17 1995-06-16 Interleukiini-5-spesifisiä yhdistelmä-vasta-aineita FI965032A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9412230A GB9412230D0 (en) 1994-06-17 1994-06-17 Interleukin-5 specific recombiant antibodies
PCT/GB1995/001411 WO1995035375A1 (fr) 1994-06-17 1995-06-16 Anticorps de recombinaison specifiques contre l'interleukine-5

Publications (3)

Publication Number Publication Date
FI965032A0 FI965032A0 (fi) 1996-12-16
FI965032L true FI965032L (fi) 1996-12-16
FI965032A7 FI965032A7 (fi) 1996-12-16

Family

ID=10756925

Family Applications (1)

Application Number Title Priority Date Filing Date
FI965032A FI965032A7 (fi) 1994-06-17 1995-06-16 Interleukiini-5-spesifisiä yhdistelmä-vasta-aineita

Country Status (18)

Country Link
US (3) US5998586A (fr)
EP (1) EP0765392B1 (fr)
JP (1) JP3973682B2 (fr)
AT (1) ATE264389T1 (fr)
AU (1) AU694783B2 (fr)
CA (1) CA2192543C (fr)
CZ (1) CZ292295B6 (fr)
DE (1) DE69532889T2 (fr)
ES (1) ES2218546T3 (fr)
FI (1) FI965032A7 (fr)
GB (1) GB9412230D0 (fr)
HU (1) HU221641B1 (fr)
IL (1) IL114179A (fr)
NO (1) NO964808L (fr)
NZ (1) NZ287927A (fr)
SK (1) SK282625B6 (fr)
WO (1) WO1995035375A1 (fr)
ZA (1) ZA954990B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
USRE39548E1 (en) 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5683892A (en) 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
ATE346867T1 (de) * 1994-12-23 2006-12-15 Smithkline Beecham Corp Rekombinante il-5 antagonisten für die behandlung von il-5 bedingten krankheiten
AU777952B2 (en) * 1999-04-23 2004-11-04 Pharmexa A/S Method for down-regulating IL5 activity
AU2007267213B2 (en) 2006-05-25 2012-03-29 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
JP5917143B2 (ja) 2008-03-28 2016-05-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 処置方法
WO2010042562A2 (fr) 2008-10-06 2010-04-15 Minerva Biotechnologies Corporation Anticorps du muc1*
CA2807552A1 (fr) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Acides nucleiques modifies et leurs procedes d'utilisation
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CA2824279A1 (fr) * 2010-12-22 2012-06-28 Cephalon Australia Pty Ltd Anticorps modifie presentant une demi-vie amelioree
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (fr) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Nucléosides, nucléotides et acides nucléiques modifiés, et leurs utilisations
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2013151663A1 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés pour la production de protéines membranaires
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
US10023638B2 (en) * 2012-12-26 2018-07-17 Oncosynergy, Inc. Anti-integrin β1 antibody compositions and methods of use thereof
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (fr) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
CN106794194A (zh) * 2014-06-30 2017-05-31 中央研究院 用于癌症治疗的介白素‑17受体b（il‑17rb）及其配体il‑17b之拮抗剂
CN116199790A (zh) 2015-02-10 2023-06-02 米纳瓦生物技术公司 人源化抗MUCl*抗体
CN116327922A (zh) 2015-08-24 2023-06-27 葛兰素史密斯克莱知识产权（第2 号）有限公司 生物医药组合物
WO2018226339A1 (fr) 2017-06-06 2018-12-13 Glaxosmithkline Llc Compositions biopharmaceutiques et procédés pour patients pédiatriques
JP7307720B2 (ja) * 2017-09-29 2023-07-12 江蘇恒瑞医薬股▲ふん▼有限公司 Ｉｌ－５抗体、その抗原結合フラグメント、およびそれらの医薬適用
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
US20220010008A1 (en) * 2018-12-12 2022-01-13 Shanghai Pharmaexplorer Co., Ltd. Anti-human interleukin 5(il-5) monoclonal antibody and use thereof
CA3134401A1 (fr) 2019-03-29 2020-10-08 Jiangsu Hengrui Medicine Co., Ltd. Composition pharmaceutique contenant un anticorps anti-il-5 et son utilisation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ES2062032T3 (es) * 1988-11-03 1994-12-16 Schering Corp Antagonista de interleuquina-5 para prevenir o reducir la eosinofilia.
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU8910891A (en) * 1990-11-20 1992-06-11 National Heart & Lung Institute, The Treatment of lung diseases
SG49597A1 (en) * 1992-02-06 1998-06-15 Schering Corp Design cloning and expression of humanized monoclonal antibodies against human interleukin-5
DE69321218T2 (de) * 1992-02-19 1999-02-18 Schering Corp., Kenilworth, N.J. Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies

Also Published As

Publication number Publication date
CZ371296A3 (cs) 1998-05-13
US5998586A (en) 1999-12-07
AU694783B2 (en) 1998-07-30
FI965032A0 (fi) 1996-12-16
IL114179A (en) 2001-08-26
ES2218546T3 (es) 2004-11-16
IL114179A0 (en) 1995-10-31
CZ292295B6 (cs) 2003-08-13
ATE264389T1 (de) 2004-04-15
WO1995035375A1 (fr) 1995-12-28
DE69532889D1 (de) 2004-05-19
JP3973682B2 (ja) 2007-09-12
GB9412230D0 (en) 1994-08-10
ZA954990B (en) 1996-12-17
EP0765392B1 (fr) 2004-04-14
NZ287927A (en) 1998-07-28
HU221641B1 (hu) 2002-12-28
HUT76672A (en) 1997-10-28
US6316227B1 (en) 2001-11-13
NO964808D0 (no) 1996-11-13
FI965032A7 (fi) 1996-12-16
SK160096A3 (en) 1997-06-04
HU9603183D0 (en) 1997-01-28
US20020042089A1 (en) 2002-04-11
CA2192543C (fr) 2008-07-29
SK282625B6 (sk) 2002-10-08
NO964808L (no) 1997-02-17
CA2192543A1 (fr) 1995-12-28
US6734286B2 (en) 2004-05-11
AU2680395A (en) 1996-01-15
DE69532889T2 (de) 2005-03-10
JPH10501697A (ja) 1998-02-17
EP0765392A1 (fr) 1997-04-02

Similar Documents

Publication Publication Date Title
FI965032A7 (fi) Interleukiini-5-spesifisiä yhdistelmä-vasta-aineita
NO955167D0 (no) Monoklonalt anti-
FI965225L (fi) Uusia peptidejä
FI961350A7 (fi) Hapteenimerkityt peptidit
NO2010013I1 (no) Rekombinant FSH-CTP
DK145493D0 (da) Antistof
DK91192D0 (da) Protein
FI971479L (fi) Fuusioituja pyrrolokarbatsoleja
FI972312L (fi) Uusia siiliperäisiä polypeptidejä
FI954147L (fi) Polypeptidejä
LV11630A (lv) T sunu antigena receptora V apgabala pilna garuma olbaltumvielas
NO976058L (no) Rekombinant mistellectin
FI952574L (fi) Glykosyylitransferaasiaktiiviset proteiinit
IS4459A (is) Ný peptíð er hafa ónæmisbreytandi áhrif
DK132892D0 (da) Proteiner
FI970168L (fi) Peptidejä
FI964363L (fi) Peptidejä
DE69411533D1 (de) Schutzbalg
DE69520771D1 (de) Faltenbalg
FI972215A7 (fi) Uusia polypeptidejä
EP0698666A3 (fr) Epimorphine modifiée
TR199701666A3 (tr) Sismanliga karsi proteinler
DK0713916T3 (da) Rekombinant beta-amylase
DE69413381D1 (de) Schutzbalg
DK120792D0 (da) Protein

Legal Events

Date Code Title Description
FD Application lapsed

Free format text: ABB OY